Company profile: Living Pharma
1.1 - Company Overview
Company description
- Provider of Personalized CAR T Cell Therapy.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Living Pharma
LadRx
HQ: United States
Website
- Description: Provider of biopharmaceutical therapeutics leveraging LADR (Linker Activated Drug Release) technology to bind anti-cancer molecules to albumin and release cytotoxic payloads at tumors, enabling higher doses with minimized off-target toxicity. Portfolio includes Aldoxorubicin, next-generation LADR-7, and Arimoclomol to amplify heat-shock proteins against protein misfolding, aggregation, and lysosomal dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LadRx company profile →
Light Chain Bio
HQ: Switzerland
Website
- Description: Provider of research and development of novel multi-specific antibodies that rely on their light chain for their function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Light Chain Bio company profile →
ECM Therapeutics
HQ: United States
Website
- Description: Provider of regenerative natural biomaterials, including extracellular matrix hydrogel for tissue regeneration, void filling, and as a drug carrier; matrix bound nanovesicles offering immunomodulation without suppression, administered intravenously or topically; and FDA-approved extracellular matrix-based surgical scaffolds for applications such as hernia repair and breast reconstruction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ECM Therapeutics company profile →
NuView Life Sciences
HQ: United States
Website
- Description: Provider of medical imaging and diagnostic solutions leveraging the NV-VPAC1 peptide to target VPAC1 receptors for PET imaging and theranostic applications. Offers in vitro urine-based diagnostic kits for detecting prostate and bladder cancer, in vivo PET agents for diagnosing breast and prostate cancer, and peptide-guided delivery of isotopes (e.g., Copper-64 for imaging, Copper-67 for treatment).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NuView Life Sciences company profile →
Propella Therapeutics
HQ: United States
Website
- Description: Provider of lymphatic-targeted oncology therapeutics and a lymphatic targeting drug delivery platform. Uses medicinal chemistry to adapt known actives with validated mechanisms for lymphatic delivery. Pipeline includes PRL-02 (abiraterone decanoate, intramuscular) for advanced prostate cancer, targeting the androgen receptor pathway by inhibiting CYP17, delivered via the lymphatic system to enhance efficacy and safety by bypassing the liver and reducing plasma exposure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Propella Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Living Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Living Pharma
2.2 - Growth funds investing in similar companies to Living Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Living Pharma
4.2 - Public trading comparable groups for Living Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →